Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $1.37 per share and revenue of $39.03 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
Ligand Pharmaceuticals Stock Performance
NASDAQ LGND opened at $120.00 on Tuesday. Ligand Pharmaceuticals has a 52-week low of $67.72 and a 52-week high of $129.90. The company has a market capitalization of $2.27 billion, a P/E ratio of 47.81 and a beta of 1.04. The company has a fifty day moving average of $113.82 and a 200-day moving average of $110.01.
Insiders Place Their Bets
In other news, CFO Octavio Espinoza sold 2,104 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $116.37, for a total transaction of $244,842.48. Following the completion of the transaction, the chief financial officer now directly owns 20,647 shares of the company’s stock, valued at approximately $2,402,691.39. This represents a 9.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John L. Lamattina sold 2,406 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $123.65, for a total transaction of $297,501.90. Following the transaction, the director now directly owns 29,515 shares of the company’s stock, valued at approximately $3,649,529.75. This trade represents a 7.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.
Analyst Ratings Changes
Read Our Latest Stock Analysis on Ligand Pharmaceuticals
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
Read More
- Five stocks we like better than Ligand Pharmaceuticals
- Insider Trades May Not Tell You What You Think
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- What Investors Need to Know to Beat the Market
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Conflicting Signals: Tempus AI’s Stock Market Rally
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.